A PT-141 dosage calculator provides laboratory researchers with precise volumetric mathematics to convert lyophilized peptide mass and diluent volume into exact research concentrations. This analytical guide details reconstitution protocol calculations, central melanocortin receptor binding profiles, and quality verification standards for preclinical research workflows.
A PT-141 dosage calculator provides laboratory researchers with precise volumetric mathematics to convert lyophilized peptide mass and diluent volume into exact research concentrations. This analytical guide details reconstitution protocol calculations, central melanocortin receptor binding profiles, and quality verification standards for preclinical research workflows.
In preclinical laboratory settings, an accurate PT-141 dosage calculator is an essential quantitative tool used to determine the exact microgram-to-microliter concentration of reconstituted PT-141 acetate. Because synthetic research peptides are supplied as lyophilized (freeze-dried) cakes to maximize shelf stability, researchers must reconstitute the compound using sterile diluents—typically bacteriostatic water or sterile 0.9% sodium chloride—prior to experimental administration in cell culture assays or rodent models.
The underlying formula for calculating research concentration ($C$) relies on dividing the total peptide mass ($M$, in milligrams or micrograms) by the total fluid volume ($V$, in milliliters or microliters): $C = M / V$. For example, reconstituting a 10 mg vial of PT-141 with 2.0 mL of diluent yields a final concentration of 5.0 mg/mL, or 5.0 µg/µL. Precise mathematical conversions prevent concentration errors during volumetric pipetting in high-throughput screening or *in vivo* animal trials.
PT-141, chemically designated as bremelanotide, is a cyclic heptapeptide derivative of native alpha-melanocyte-stimulating hormone (α-MSH). Unlike non-selective melanocortin peptides, PT-141 exhibits potent agonist activity primarily at the central melanocortin sub-type 3 (MC3R) and sub-type 4 (MC4R) receptors located in the hypothalamus, while demonstrating reduced affinity for peripheral MC1R receptors compared to parent compounds.
Preclinical binding assays indicate that activation of central MC4R pathways by PT-141 initiates downstream neuronal signaling, modulating central nervous system pathways linked to sexual-health pathways, appetitive behavior, and vascular tone. In rodent models, researchers utilize quantified micro-injections into targeted brain regions—such as the medial preoptic area (mPOA)—to study the neurochemical cascades mediated by intracellular cyclic adenosine monophosphate (cAMP) accumulation following receptor binding.
Preclinical investigations over the past two decades have established PT-141 as a primary tool compound for investigating central regulation of physiological arousal and motivation. Animal studies published in peer-reviewed neuropharmacology journals demonstrate that central or systemic administration of PT-141 induces significant copulatory behavior and erection responses in male rodent models, operating independently of the nitric oxide / PDE5 inhibitor pathway.
In female rodent models, researchers have documented marked increases in solicitous and appetitive behaviors following systemic administration of PT-141. Because its mechanism of action bypasses direct vascular smooth muscle targets and instead modulates central hypothalamic neural circuits, researchers frequently employ PT-141 in comparative studies alongside non-selective peptides listed across our all peptides catalog to isolate specific MC4R-mediated signaling outcomes.
To ensure precise volumetric dosing when utilizing a PT-141 dosage calculator, research staff must follow standardized laboratory protocols for peptide reconstitution. All procedures should be conducted within a certified laminar flow hood utilizing aseptic technique to preserve product integrity and prevent microbial contamination.
The standard laboratory reconstitution process involves the following sequential steps:
1. Remove the protective flip-off cap from the lyophilized PT-141 vial and sanitize the rubber stopper with a 70% isopropyl alcohol wipe. 2. Using a calibrated laboratory syringe, draw the predetermined volume of bacteriostatic water (e.g., 1.0 mL or 2.0 mL) specified in your experimental protocol. 3. Position the needle tip against the inner glass wall of the vial, slowly depressing the plunger so the liquid flows down the side rather than splashing directly onto the lyophilized cake. 4. Gently swirl the vial in a circular motion until the peptide cake is completely dissolved into a clear, colorless solution. Never shake the vial vigoriously, as mechanical agitation can induce shear stress and protein denaturation. 5. Allow the reconstituted solution to equilibrate at room temperature for 5 minutes prior to analytical measurement or aliquoting.
To streamline calculations in the laboratory, researchers refer to standardized concentration tables matching specific lyophilized vial masses with common diluent volumes. The table below outlines volumetric concentrations for a standard 10 mg PT-141 research vial across typical dilution ratios used in laboratory research experiments:
• **10 mg PT-141 + 1.0 mL Diluent**: Final Concentration = 10.0 mg/mL (10.0 µg/µL or 100 µg per 10 U / 0.1 mL unit). • **10 mg PT-141 + 2.0 mL Diluent**: Final Concentration = 5.0 mg/mL (5.0 µg/µL or 50 µg per 10 U / 0.1 mL unit). • **10 mg PT-141 + 2.5 mL Diluent**: Final Concentration = 4.0 mg/mL (4.0 µg/µL or 40 µg per 10 U / 0.1 mL unit). • **10 mg PT-141 + 5.0 mL Diluent**: Final Concentration = 2.0 mg/mL (2.0 µg/µL or 20 µg per 10 U / 0.1 mL unit).
For small-animal research models (e.g., mice or Sprague-Dawley rats), higher diluent volumes (such as 5.0 mL) are frequently selected to allow precise administration of micro-gram quantities using standard laboratory micropipettes without exceeding volumetric limits per injection site. For broader reconstitution formulas across varied peptide structures, researchers can consult our dedicated peptide reconstitution calculator guide.
Within the melanocortinergic research field, researchers frequently contrast PT-141 against structurally related synthetic analogs and endogenous ligands. Native endogenous α-MSH serves as the baseline non-selective agonist across MC1R, MC3R, MC4R, and MC5R receptors, but exhibits an extremely short enzymatic half-life in physiological matrices.
In contrast, synthetic cyclic peptides demonstrate significantly enhanced enzymatic stability. While Melanotan II retains strong agonist activity at peripheral MC1R receptors—inducing marked melanogenesis alongside central receptor activation—PT-141 was specifically synthesized with a modified C-terminal amino acid structure to isolate central MC3R/MC4R signaling pathways. This divergence in receptor selectivity makes PT-141 the preferred tool compound when investigating central sexual-health pathways without confounding peripheral skin pigmentation signaling pathways.
Lyophilized PT-141 acetate demonstrates superior thermodynamic stability when stored in cold temperatures. Unreconstituted vials should be preserved at -20°C in a desiccated environment, shielded from light exposure. Under these conditions, the lyophilized compound retains structural stability for up to 24 months from the manufacturing date.
Once reconstituted with bacteriostatic water containing 0.9% benzyl alcohol, liquid PT-141 solutions should be stored at 2°C to 8°C (refrigerated) and utilized within 28 to 30 days. For long-term preclinical studies requiring extended storage of reconstituted material, solution aliquoting into single-use polypropylene microtubes followed by immediate deep-freezing at -80°C is recommended to prevent degradation caused by repeated freeze-thaw cycles.
To obtain reproducible data in preclinical research, laboratory investigators must ensure that research peptides meet strict analytical benchmarks. Every lot of PT-141 supplied by PX1 Research undergoes rigorous testing in accredited laboratory environments prior to distribution.
Purity is verified via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC), ensuring a minimum purity profile of ≥99.0%. Molecular identity and correct amino acid sequence conformation are confirmed via Electrospray Ionization Mass Spectrometry (ESI-MS). Furthermore, because residual bacterial lipopolysaccharides can alter baseline inflammatory cascades in central nervous system research, our peptides undergo Limulus Amebocyte Lysate (LAL) testing to confirm endotoxin levels remain strictly below <0.05 EU/mg. Every shipment includes a lot-specific Certificate of Analysis (COA) traceable directly to our ISO 17025 accredited laboratory partners.
PX1 Research is a leading supplier of USA-manufactured research peptides tailored specifically for academic, biotechnology, and institutional research facilities. All compounds are synthesized in state-of-the-art, GMP-compliant manufacturing facilities adhering to ISO 9001 and ISO 17025 quality management standards.
Orders placed Monday through Friday ship same-day from our strategically positioned distribution hubs in California and Arizona, ensuring rapid transit times and minimal temperature exposure. Principal investigators and lab managers establishing bulk evaluation models or ongoing research series can access specialized tiered pricing through our dedicated wholesale laboratory account portal.
What is a PT-141 dosage calculator used for in laboratory settings?
A PT-141 dosage calculator is a mathematical tool used by researchers to determine the precise volume of diluent (e.g., bacteriostatic water) required to reconstitute a known mass of lyophilized PT-141 peptide to achieve a specific target concentration (mg/mL or µg/µL) for in vitro or animal model dosing.
How do you calculate concentration after reconstituting 10 mg of PT-141?
Concentration is calculated by dividing total peptide mass by total diluent volume. Reconstituting a 10 mg vial of PT-141 with 2.0 mL of bacteriostatic water yields a final concentration of 5.0 mg/mL (or 5.0 µg/µL).
What melanocortin receptors does PT-141 selectively target?
Preclinical receptor binding studies show that PT-141 acts primarily as an agonist at the central melanocortin sub-type 3 (MC3R) and sub-type 4 (MC4R) receptors located in the hypothalamus, with substantially reduced affinity for peripheral MC1R receptors compared to Melanotan II.
What diluent should be used for reconstituting PT-141 for research?
Bacteriostatic water (0.9% benzyl alcohol preserved) or sterile 0.9% sodium chloride solution is standard for laboratory reconstitution. Bacteriostatic water prevents microbial growth, allowing multiple volumetric draws over a 30-day period when refrigerated at 2°C–8°C.
How should reconstituted PT-141 solutions be stored in the lab?
Reconstituted PT-141 solutions should be kept refrigerated at 2°C to 8°C and protected from light, remaining stable for up to 30 days. For longer storage, solutions should be aliquoted and maintained at -80°C to prevent freeze-thaw degradation.
What analytical standards verify the purity of PX1 Research PT-141?
PX1 Research verifies PT-141 lot purity using RP-HPLC (verifying ≥99% purity) and confirms mass identity via ESI-MS. Additionally, bacterial endotoxin testing via LAL assay ensures levels remain below <0.05 EU/mg, with lot-specific COAs provided.
How does PT-141 differ from Melanotan II in preclinical research?
While Melanotan II is a non-selective melanocortin agonist with high affinity for MC1R (inducing skin pigmentation), PT-141 is a modified cyclic peptide designed to selectively target central MC3R/MC4R pathways involved in sexual-health pathways without prominent peripheral melanogenic effects.
Is PT-141 supplied by PX1 Research intended for human consumption?
No. All products supplied by PX1 Research, including PT-141, are strictly for laboratory research, in vitro, and preclinical research use only. They are not intended for human or animal diagnostic, therapeutic, or clinical applications.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.